SIGMAR1 and Alzheimer disease: In vivo stroke model, with using immunohistochemistry assays, it was shown that after treatment of a novel Sig-1R agonist, aniline derivative compound (Comp-AD) significantly reduced the expression of PERK (Morihara et al., 2018).